

CORDLIFE GROUP LIMITED
(Company Registration No.: 200102883E)
(Incorporated in the Republic of Singapore)

UPDATE ON NOTICE FROM THE MINISTRY OF HEALTH

The Board of Directors (the "**Board**") of Cordlife Group Limited (the "**Company**" and together with its subsidiaries, the "**Group**") refers to its announcements dated 30 November 2023, 13 December 2023, 15 December 2023, 17 January 2024, 23 January 2024, 8 April 2024 and 28 May 2024 (collectively, the "**Announcements**") relating to, among others, the issuance of a further notice from the Ministry of Health ("**MOH**") to stop the collection, testing, processing and/or storage of any new cord blood for up to an additional three months with effect on and from 15 June 2024 or unless sooner approved by the Director-General of Health (the "**Second Notice**"), and the Company's intention not to submit written representations to the MOH with respect to the contents of the Second Notice and to inform the MOH of the same.

The Company wishes to inform that it has received a letter from the MOH informing that the MOH has considered the Company's response to the Second Notice, and has directed the Company to give effect to the contents of the Second Notice with effect on and from 15 June 2024.

As stated previously, the Company has been making efforts towards implementing appropriate rectification measures to address all areas of non-compliance with the Regulations, and will update the MOH on its progress to fulfil all requirements and receive approval to resume operations as soon as possible.

As the MOH investigations are still ongoing, the Company is unable to assess the exact financial impact on the financial performance of the Group for the financial year ending 31 December 2024. However, the continued suspension of the Group's operations in Singapore in relation to its cord blood banking services, along with the fixed costs being incurred during such suspension, is expected to continue to have a negative financial impact on the Group.

In the meantime, shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company. They should consult their stockbrokers, bank managers, solicitors, or other professional advisers if they have any doubt about the actions they should take.

The Company will update its shareholders and the investing public if there are any material developments in relation to the above, in accordance with the requirements of the SGX-ST listing rules.

For and on behalf of the Board
CORDLIFE GROUP LIMITED

Ivan Yiu Pang Fai
Group CEO

18 June 2024